Navigation Links
Repligen Receives Notice of Allowance for Recombinant Protein A Patent
Date:2/3/2010

WALTHAM, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. The patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities.  This product has been developed as an alternative to the legacy Staphylococcus aureus Protein A and will be the basis of Repligen's future chromatography product development.  Proteins manufactured with recombinant technology have multiple advantages over a natural source such as Staphylococcus aureus including higher quality, product consistency and purity as well as improved supply chain security and a lower cost of production.

"This action by the patent office reflects our continuing investment and commitment to our Bioprocessing business," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "This recently launched recombinant Protein A product is an important step in expanding our business through both organic growth and product acquisition."

Repligen is the world's leading supplier of recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, a highly successful class of biopharmaceutical.  There are currently more than 25 monoclonal antibodies that have received regulatory approval with more than 200 products in various stages of clinical
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today announced that Robert A. Ingram has ... is an ardent champion for innovation in the lifesciences industry, ... on Edwards, board as we pursue our focused innovation strategy," ... "Bob has provided a valuable perspective to our board, drawing ...
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... Pilot Study Demonstrates 50% ... ANNAPOLIS, Md., March 29, 2007,/PRNewswire-FirstCall/ -- Medarex, Inc. ... a privately held,biotechnology company dedicated to the development ... human,monoclonal antibody product candidate being developed for the,prevention ...
... DIEGO--(BUSINESS WIRE)--Mar 29, 2007 - ACADIA Pharmaceuticals,Inc. ... to fuel drug discovery and clinical,development of ... announced that the company will present at ... from,March 28 through April 1, 2007, in ...
Cached Medicine Technology:Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 8ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 2ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 3ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 5
(Date:7/31/2015)... York (PRWEB) , ... July ... ... attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now available ... 2015 was well received with a 94% approval rating from the nationwide ...
(Date:7/31/2015)... ... July 31, 2015 , ... As part of their ... involvement and support of animal welfare organizations is essential to the longevity of their ... year in the National Association of Professional Pet Sitters (NAPPS) annual Presents 4 Pets ...
(Date:7/31/2015)... ... ... Transfinder, a software company based in Schenectady, N.Y., achieved record revenue for ... the first six months ended June 30, 2015 compared with the same period in ... record-revenue mark of $10.4 million. , “We know what our customers need and want ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t ... the industry’s premier thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International ... event attracts over 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... firm, has been recognized in the 2015 Aster Awards national competition for a ... organization serving Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. ...
Breaking Medicine News(10 mins):Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2
... Dinoire’s countenance has changed 360 degrees in comparison to how ... the first patient in the world to undergo a// partial ... year ago, combined the dexterity of a 50 member team, ... has recovered very well. ,Miss Dinoire, 39, ...
... Maldives men's volleyball team lost to Chinese Taipei (Taiwan) in ... three of its players were confirmed to have chicken// pox. ... Asian Volleyball Confederation (AVC) said in a statement. ... pox. The disease spreads easily and we have to make ...
... in Mumbai suffers from backache, caused mainly by the poor ... out by Health India, a New Delhi-based non-profit group, the ... Delhi and 77 percent in Mumbai who use public transport ... ,"Bad roads, overcrowded public transport systems, poor quality of ...
... revealed that first time ecstasy users may suffer impaired memory and ... areas of the brain. , ,'We do not know if ... the University of Amsterdam, who led the study. 'Therefore, we cannot ... brain, and people should be informed of this risk.' ...
... the United Kingdom concluded that the UK's National Health ... least// for now. The review was published in the ... series of the Health Technology Assessment Programme, part of ... Kingdom. ,An implantable pump can help heart ...
... you hate being told to sit upright by others, because ... indeed what suits your// body better. Sitting ramrod straight may ... team of Scottish radiologists presented their findings recently at Chicago.They ... monitored using a specialized MRI scanner that could record their ...
Cached Medicine News:Health News:Maldives Volleyball Team Members Affected by Chickenpox 2Health News:Public Transport Causing Backaches in Delhi, Mumbai 2Health News:Review Urges Restricted Use Of Devices To Keep Heart Patients Alive 2Health News:Review Urges Restricted Use Of Devices To Keep Heart Patients Alive 3
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
... sulfate (DHEA-S) is the sulfate ester of ... enzymatic conversion of DHEA in adrenal and ... steroid secreted by the adrenal cortex, and ... biosynthesis. DHEA possesses relatively weak androgenic activity, ...
... DSL's unique DHEA-S-7kits ... antiserum targeted against the ... DHEA-S molecule, with no ... DHEA-S Saliva RIA has ...
... is based on the competition principle and ... DHEA-S present in the sample and a ... peroxidase compete for the binding sites of ... wells. After one hour incubation the microtiterplate ...
Medicine Products: